Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sutro Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.04 |
52 Week High | US$6.13 |
52 Week Low | US$2.01 |
Beta | 1.22 |
11 Month Change | -0.74% |
3 Month Change | 0.75% |
1 Year Change | -4.04% |
33 Year Change | -78.09% |
5 Year Change | -51.33% |
Change since IPO | -73.42% |
Recent News & Updates
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Recent updates
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Shareholder Returns
STRO | US Biotechs | US Market | |
---|---|---|---|
7D | 25.5% | 2.7% | 4.0% |
1Y | -4.0% | 15.4% | 24.9% |
Return vs Industry: STRO underperformed the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: STRO underperformed the US Market which returned 21.7% over the past year.
Price Volatility
STRO volatility | |
---|---|
STRO Average Weekly Movement | 12.2% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: STRO's share price has been volatile over the past 3 months.
Volatility Over Time: STRO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 304 | Bill Newell | www.sutrobio.com |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Sutro Biopharma, Inc. Fundamentals Summary
STRO fundamental statistics | |
---|---|
Market cap | US$294.25m |
Earnings (TTM) | -US$124.45m |
Revenue (TTM) | US$169.36m |
2.0x
P/S Ratio-2.7x
P/E RatioIs STRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
STRO income statement (TTM) | |
---|---|
Revenue | US$169.36m |
Cost of Revenue | US$218.33m |
Gross Profit | -US$48.97m |
Other Expenses | US$75.48m |
Earnings | -US$124.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.52 |
Gross Margin | -28.92% |
Net Profit Margin | -73.48% |
Debt/Equity Ratio | 0% |
How did STRO perform over the long term?
See historical performance and comparison